Purchase Order 75N91020P00715

<p>The National Cancer Institute awarded a purchase order to Advanced Cell Diagnostics, Inc. for laboratory and testing services valued at $12,345.00, effective August 6, 2020. Performance will take place in Newark, California, with ultimate completion by September 4, 2020. The order carries firm fixed pricing and no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Advanced Cell Diagnostics, Inc. valued at $13,814.40 on September 17, 2020, with completion targeted for November 26, 2020. The order carries firm fixed pricing with no small business set-aside. Performance occurs in Newark, California. The purchase order procures RNA detection technologies and related diagnostic products from Advanced Cell Diagnostics' RNAscope platform for cancer research support.</p>

The National Cancer Institute awarded a purchase order to Advanced Cell Diagnostics, Inc. for $10,464.00 on May 19, 2021, for biological and reagent material on a firm fixed price basis. No set-aside was used. Place of performance is Newark, California. The order was issued to administratively de-obligate unexpended and expiring fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a) in preparation for September 30, 2026 closing of the period of availability. Ultimate completion...

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $17,696 firm fixed price purchase order to Advanced Cell Diagnostics, Inc. of Newark, California for lab testing services. As the prime contractor, Advanced Cell Diagnostics will provide the requested testing services to the agency. Advanced Cell Diagnostics is a subsidiary of Bio-Techne Corporation, located in Newark. The award does not have a set-aside designation. The contract has a...

<p>The National Cancer Institute awarded a purchase order to Advanced Cell Diagnostics, Inc. valued at $11,593.00 on May 28, 2021, for RNAscope technology and related reagents. Work is performed in Newark, California. The purchase order, issued under firm fixed-price terms with no set-aside, provides RNA detection and visualization capabilities for identifying TGF-beta isoforms in normal tissues and tumors using minimal sample material. The order closes on June 27, 2021.</p>

<p>The National Institutes of Health Clinical Center awarded a purchase order to Advanced Cell Diagnostics, Inc. valued at $10,807.60 on August 22, 2018, for RNA probes and advanced cell diagnostics products. Performance is located in Newark, California. The order carries a firm fixed price, with an ultimate completion date of August 30, 2018. No set-aside category applies.</p>

<p>The National Institute of Nursing Research awarded a purchase order to Advanced Cell Diagnostics, Inc. valued at $10,817.20 on August 28, 2018, with completion targeted for September 28, 2018. The order is for RNA detection technologies and related diagnostic products, with performance at the vendor's Newark, California facility. No small business set-aside applied.</p>

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $13,128 purchase order to Advanced Cell Diagnostics, Inc., doing business as ACD, for reagents. ACD is a division of Bio-Techne Corporation, doing business as Bio-Techne. The firm fixed price order runs from July 31, 2023 through August 31, 2023 for delivery to ACD's Newark, California facility. No additional details were provided on the original solicitation, major subcontractors, or...

The Department of Health and Human Services National Institutes of Health Clinical Center awarded a $16,580 firm fixed price purchase order to Advanced Cell Diagnostics, Inc. for RNAScope under contract number 1187802. Advanced Cell Diagnostics, Inc. will deliver its cell diagnostics technology from its Newark, California location under the eight-month contract ending in March 2024. As part of the National Institutes of Health's medical research efforts, this contract provides RNAScope, a...

The Department of Health and Human Services National Institutes of Health Clinical Center awarded a $13,507.60 firm fixed price purchase order to Advanced Cell Diagnostics, Inc. for advanced cell diagnostics services. Advanced Cell Diagnostics, Inc. will perform as the prime contractor, with its parent company listed as Bio-Techne Corporation. The contract period of performance is from November 13, 2023 through January 5, 2024. It is presumed Advanced Cell Diagnostics, Inc. will provide their...